SCHERING AG RECEIVES EU APPROVAL FOR NOVEL CONTRAST AGENT VASOVIST
Schering AG, Germany recently announced that Vasovist (gadofosveset trisodium),
its novel contrast agent for magnetic resonance angiography, has been approved
by the European Commission in all 25 member states of the EU. Vasovist is an
innovative blood pool contrast agent indicated for visualization of abdominal
or limb vessels in patients with known or suspected vascular disease such as
stenosis and aneurysms.